Leads Biolabs Updates Board Composition and Committee Structure

Bulletin Express05-15

Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive directors, three non-executive directors and three independent non-executive directors.

Executive directors include Dr. Kang Xiaoqiang, who simultaneously serves as Chairman, Chief Executive Officer and General Manager, alongside Dr. Lai Shoupeng and Mr. Zuo Honggang.

Non-executive directors are Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan.

Independent oversight is provided by Dr. Zhang Hongbing, Mr. Du Yilong (designated lead independent director) and Ms. Du Jiliu.

Committee leadership has been clarified: • Audit Committee—Chaired by Dr. Zhang Hongbing. • Nomination Committee—Chaired by Mr. Du Yilong. • Remuneration Committee—Chaired by Ms. Du Jiliu.

Dr. Kang Xiaoqiang, Mr. Zhang Yincheng and Dr. Chen Renhai hold member positions on at least one committee, underscoring executive and non-executive participation in governance. The announcement formalises current governance roles and affirms compliance with Hong Kong-listed company standards.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136090386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-15 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136090386","market":"hk","top_or_hot":-1,"title":"Leads Biolabs Updates Board Composition and Committee Structure","media":"Bulletin Express","content":"<p>Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive directors, three non-executive directors and three independent non-executive directors.</p>\n<p>Executive directors include Dr. Kang Xiaoqiang, who simultaneously serves as Chairman, Chief Executive Officer and General Manager, alongside Dr. Lai Shoupeng and Mr. Zuo Honggang.</p>\n<p>Non-executive directors are Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan.</p>\n<p>Independent oversight is provided by Dr. Zhang Hongbing, Mr. Du Yilong (designated lead independent director) and Ms. Du Jiliu.</p>\n<p>Committee leadership has been clarified:  \n• Audit Committee—Chaired by Dr. Zhang Hongbing.  \n• Nomination Committee—Chaired by Mr. Du Yilong.  \n• Remuneration Committee—Chaired by Ms. Du Jiliu.</p>\n<p>Dr. Kang Xiaoqiang, Mr. Zhang Yincheng and Dr. Chen Renhai hold member positions on at least one committee, underscoring executive and non-executive participation in governance. The announcement formalises current governance roles and affirms compliance with Hong Kong-listed company standards.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leads Biolabs Updates Board Composition and Committee Structure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeads Biolabs Updates Board Composition and Committee Structure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-15 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive directors, three non-executive directors and three independent non-executive directors.</p>\n<p>Executive directors include Dr. Kang Xiaoqiang, who simultaneously serves as Chairman, Chief Executive Officer and General Manager, alongside Dr. Lai Shoupeng and Mr. Zuo Honggang.</p>\n<p>Non-executive directors are Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan.</p>\n<p>Independent oversight is provided by Dr. Zhang Hongbing, Mr. Du Yilong (designated lead independent director) and Ms. Du Jiliu.</p>\n<p>Committee leadership has been clarified:  \n• Audit Committee—Chaired by Dr. Zhang Hongbing.  \n• Nomination Committee—Chaired by Mr. Du Yilong.  \n• Remuneration Committee—Chaired by Ms. Du Jiliu.</p>\n<p>Dr. Kang Xiaoqiang, Mr. Zhang Yincheng and Dr. Chen Renhai hold member positions on at least one committee, underscoring executive and non-executive participation in governance. The announcement formalises current governance roles and affirms compliance with Hong Kong-listed company standards.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1136090386","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136090386","pubTimestamp":1778837016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B"},"translate_title":"Leads Biolabs更新董事会组成和委员会结构","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive directors, three non-executive directors and three independent non-executive directors.\nExecutive directors include Dr. Kang Xiaoqiang, who simultaneously serves as Chairman, Chief Executive Officer and General Manager, alongside Dr. Lai Shoupeng and Mr. Zuo Honggang.\nNon-executive directors are Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan.\nIndependent oversight is provided by Dr. Zhang Hongbing, Mr. Du Yilong (designated lead independent director) and Ms. Du Jiliu.\nCommittee leadership has been clarified:  \n• Audit Committee—Chaired by Dr. Zhang Hongbing.  \n• Nomination Committee—Chaired by Mr. Du Yilong.  \n• Remuneration Committee—Chaired by Ms. Du Jiliu.\nDr. Kang Xiaoqiang, Mr. Zhang Yincheng and Dr. Chen Renhai hold member positions on at least one committee, underscoring executive and non-executive participation in governance. The announcement formalises current governance roles and affirms compliance with Hong Kong-listed company standards.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136090386","isCrawlerRequest":true}